Advanced Immunocompetent Primary Human Airway Models for Respiratory Disease Modeling
Advancements in human-relevant in vitro models are transforming how respiratory diseases are studied and how drug safety and efficacy are evaluated. This webinar will introduce a comprehensive panel of advanced air-liquid interface (ALI) primary human airway models that closely replicate the physiology of the human respiratory tract.
Covering multiple regions including nasal, tracheal, bronchial, small airway, and alveolar epithelia, these models provide a powerful platform for studying respiratory biology, disease mechanisms, and inhalation toxicology. The session will also explore how co-culturing with immune cells enhances physiological relevance, enabling more predictive and translational outcomes.
Join this session to understand how next-generation airway models are supporting drug discovery, reducing reliance on animal testing, and improving the accuracy of preclinical research.
Speaker
Dr. Samuel Constant
Co-Founder and CEO | Epithelix
Dr. Samuel Constant, Ph.D., is the Co-Founder and Chief Executive Officer of Epithelix, where he leads the company's global management, strategic direction, business development, and partnerships across its Swiss and French operations. A synthetic organic chemist by training, Dr. Constant has over 20 years of international research experience, having worked across Switzerland, France, the United Kingdom, and Japan. He has extensive expertise in in vitro test method development, particularly in the advancement of human-relevant respiratory models for biomedical research and drug development. Dr. Constant has co-authored more than 150 scientific publications and has received 18 awards recognizing his contributions to scientific research, technological innovation, and business development.
Key Learning Objectives
- Overview of advanced air-liquid interface (ALI) respiratory models covering nasal, tracheal, bronchial, small airway, and alveolar epithelia
- Understanding human-relevant in vitro models and how they mimic real airway structure and function
- Applications in respiratory toxicity assessment, including inflammation, immune response, and epithelial barrier integrity
- Use of these models for drug safety testing and preclinical evaluation of APIs and therapeutic candidates
- Role of ALI models in respiratory disease modeling and translational research
Watch Now: Advanced Immunocompetent Primary Human Airway Models for Respiratory Disease Modeling
This webinar is available on demand. Fill in the form to watch the full recording — we'll email you the link too.
- April 17, 2026 · 2:30 to 3:30 PM
- Dr. Samuel Constant, Epithelix
- kbiinfo@krishgen.com
- +91 22 49198700
Your details
Request the recording
Fill in your details and you'll go straight to the recording — we'll also email you the link.
More Webinars
Shortcuts to Discovery and Characterization of Monoclonal Antibodies
Monoclonal antibody (mAb) discovery and characterization often face significant delays due to iterative screening cycles, late-stage functional failures, and downstream analytical bottlenecks. This webinar details five practical shortcuts that accelerate timelines from target validation to preclinical characterization.
View Webinar June 12, 2026Viral Vectors & CRISPR for Building Disease Models
Gene editing and viral vector technologies are transforming the development of advanced disease models for translational research.
View Webinar September 19, 20253D Cell Culture & Organoids: Bridging Basic Research and Clinical Translation
The landscape of biomedical research is rapidly evolving with the advent of advanced 3D cell culture and organoid technologies. While traditional 2D systems have long been the foundation of experimental biology, they often lack the physiological relevance needed for accurate translational outcomes.
View Webinar